Amendment ID: S2499-31-R1

Redraft Amendment 31

Manufacturer Disclosure of Eligible Drug Pricing Information

Ms. Rausch moves that the proposed new draft be amended in section 21, in the proposed second paragraph of subsection (b) of section 21 of chapter 6D of the General Laws, by striking out the first sentence and inserting in place thereof the following 2 sentences:- “In conducting a review of eligible drugs, the commission may request information relating to the pricing of an eligible drug from the manufacturer of said eligible drug. Upon receiving a request for information from the commission, a manufacturer shall disclose to the commission, within a reasonable time period, as determined by the commission, applicable information relating to the manufacturer’s pricing of an eligible drug.”.